These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 38053307

  • 1. Emtricitabine/tenofovir alafenamide usage in a Scottish sexual health service providing HIV pre-exposure prophylaxis: A service evaluation.
    Burley N, MacDonald R, Khan A.
    Int J STD AIDS; 2024 Mar; 35(4):308-310. PubMed ID: 38053307
    [Abstract] [Full Text] [Related]

  • 2. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G, Sauermilch D, Gandhi M, Starks TJ.
    AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
    [Abstract] [Full Text] [Related]

  • 3. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo AB, Westmoreland DA, Carneiro PB, Johnson J, Grov C.
    AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
    [Abstract] [Full Text] [Related]

  • 4. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
    Okochi H, Louie A, Phung N, Zhang K, Tallerico RM, Kuncze K, Spinelli MA, Koss CA, Benet LZ, Gandhi M.
    Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
    [Abstract] [Full Text] [Related]

  • 5. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD.
    Ann Intern Med; 2020 May 05; 172(9):583-590. PubMed ID: 32150602
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
    Massud I, Cong ME, Ruone S, Holder A, Dinh C, Nishiura K, Khalil G, Pan Y, Lipscomb J, Johnson R, Deyounks F, Rooney JF, Babusis D, Park Y, McCallister S, Callebaut C, Heneine W, García-Lerma JG.
    J Infect Dis; 2019 Oct 22; 220(11):1826-1833. PubMed ID: 31362305
    [Abstract] [Full Text] [Related]

  • 7. No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis.
    Patel N, Morris S, Burke L, Chow K, Pacheco D, Anderson P, Stancyzk F, Blumenthal J.
    Br J Clin Pharmacol; 2024 Oct 22; 90(10):2360-2365. PubMed ID: 38646796
    [Abstract] [Full Text] [Related]

  • 8. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
    Yager J, Castillo-Mancilla J, Ibrahim ME, Brooks KM, McHugh C, Morrow M, McCallister S, Bushman LR, MaWhinney S, Kiser JJ, Anderson PL.
    J Acquir Immune Defic Syndr; 2020 Jul 01; 84(3):323-330. PubMed ID: 32539288
    [Abstract] [Full Text] [Related]

  • 9. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
    Mandal S, Kang G, Prathipati PK, Zhou Y, Fan W, Li Q, Destache CJ.
    J Control Release; 2019 Jan 28; 294():216-225. PubMed ID: 30576746
    [Abstract] [Full Text] [Related]

  • 10. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E.
    Biochem Pharmacol; 2016 Nov 01; 119():1-7. PubMed ID: 27133890
    [Abstract] [Full Text] [Related]

  • 11. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
    Haaland RE, Martin A, Livermont T, Fountain J, Dinh C, Holder A, Lupo LD, Hall L, Conway-Washington C, Kelley CF.
    J Acquir Immune Defic Syndr; 2019 Nov 01; 82(3):252-256. PubMed ID: 31335590
    [Abstract] [Full Text] [Related]

  • 12. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Martín-Herranz I, Míguez-Rey E, Poveda E, Castro-Iglesias Á.
    Basic Clin Pharmacol Toxicol; 2019 Apr 01; 124(4):479-490. PubMed ID: 30388308
    [Abstract] [Full Text] [Related]

  • 13. HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo.
    Zivich PN, Cole SR, Edwards JK, Glidden DV, Das M, Shook-Sa BE, Shao Y, Mehrotra ML, Adimora AA, Eron JJ.
    J Infect Dis; 2024 Apr 12; 229(4):1123-1130. PubMed ID: 37969014
    [Abstract] [Full Text] [Related]

  • 14. Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
    Devred I, Kayembe K, Valin N, Rougier H, Shinga BW, Lambert-Niclot S, Chiarabini T, Meyohas MC, Lacombe K.
    BMC Infect Dis; 2023 Sep 04; 23(1):578. PubMed ID: 37667182
    [Abstract] [Full Text] [Related]

  • 15. Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
    Bekerman E, Cox S, Babusis D, Campigotto F, Das M, Barouch DH, Cihlar T, Callebaut C.
    J Antimicrob Chemother; 2021 Feb 11; 76(3):692-698. PubMed ID: 33202006
    [Abstract] [Full Text] [Related]

  • 16. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, Post FA, Morales-Ramirez J, Thompson M, Osiyemi O, Rashbaum B, Stellbrink HJ, Martorell C, Liu H, Liu YP, Porter D, Collins SE, SenGupta D, Das M.
    HIV Med; 2018 Nov 11; 19(10):724-733. PubMed ID: 30101539
    [Abstract] [Full Text] [Related]

  • 17. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.
    De Clercq E.
    Biochem Pharmacol; 2018 Jul 11; 153():2-11. PubMed ID: 29225131
    [Abstract] [Full Text] [Related]

  • 18. A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
    Garrett KL, Chen J, Maas BM, Cottrell ML, Prince HA, Sykes C, Schauer AP, White N, Dumond JB.
    J Pharmacol Exp Ther; 2018 Nov 11; 367(2):245-251. PubMed ID: 30150483
    [Abstract] [Full Text] [Related]

  • 19. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B, Rossi C, Côté-Sergent A, Bookhart B, Anderson D, Lefebvre P, Lafeuille MH, Donga P.
    Curr Med Res Opin; 2022 Feb 11; 38(2):287-298. PubMed ID: 34812097
    [Abstract] [Full Text] [Related]

  • 20. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
    Imaz A, Podzamczer D.
    Expert Rev Anti Infect Ther; 2017 Mar 11; 15(3):195-209. PubMed ID: 28117606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.